Updates are available Correction dated 2024-04-01
Click to view Correction: https://doi.org/10.1038/s12276-024-01217-y
-
Authors
Kim, Tae-Kyung
Bae, Eun-Jin https://orcid.org/0000-0002-4369-7405
Jung, Byung Chul
Choi, Minsun
Shin, Soo Jean
Park, Sung Jun
Kim, Jeong Tae
Jung, Min Kyo
Ulusoy, Ayse
Song, Mi-Young
Lee, Jun Sung
Lee, He-Jin
Di Monte, Donato A.
Lee, Seung-Jae
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2018R1A5A2025964, NRF-2019R1I1A1A01063394, NRF-2020R1C1C1008911)
Ministry of Science, ICT and Future Planning (21-BR-01-11 to MKJ)
Innovative Medicines Initiative (IMI-2 821522, PD-MitoQUANT)
EU Joint Programme – Neurodegenerative Disease Research (JPND 01ED2005B)
- License Information
-
More Information
Article History
Received: 20 October 2021
Revised: 27 September 2022
Accepted: 5 October 2022
First Online: 6 December 2022
Change Date: 1 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s12276-024-01217-y
Competing interests
: S-JL is a co-founder and CEO of Neuramedy Co. Ltd., and JSL is employed by Neuramedy Co. Ltd. The authors declare no competing interests.
